Insilico Medicine
Generative AI software for drug discovery, scientific research, and sustainability.
Insilico Medicine is an end-to-end generative AI-driven biotechnology company that accelerates drug discovery and development. The company utilizes its proprietary Pharma.AI platform to identify disease targets, generate novel molecular structures, and predict clinical trial outcomes. Its pipeline includes therapeutic programs for idiopathic pulmonary fibrosis, oncology, and inflammatory diseases.
The company serves the pharmaceutical and biotechnology industries, providing software tools and collaborating with global industry leaders to bring life-saving medications to patients more efficiently. Its platform integrates biology, chemistry, and clinical development data to reduce the time and cost associated with traditional drug R&D.
Insilico Medicine is also active in longevity research and environmental sustainability, developing AI models to predict biological age and optimize sustainable product innovation. The company is headquartered in Hong Kong and New York, with a significant global presence across the U.S., Greater China, Canada, and the Middle East.
- Website: insilico.com
Industries: Biotechnology, Pharmaceuticals
Categories: Drug Discovery, Generative AI
AntSpace put this profile together from public information. It may be incomplete; once Insilico Medicine claims it, its admins can edit everything here.
Our culture
Insilico Medicine describes its culture through values such as "Patient First," "Relentless Innovation," and "Transparency & Integrity." The company emphasizes "Highest Quality & Reproducibility" in its scientific work and fosters "Global Partnerships" to validate its platform. Its team is distributed globally, with a presence in key geographies to support recruitment of top scientific talent and build relationships with biopharma partners and investors.
Core values
- Patient First
- Relentless Innovation
- Transparency & Integrity
- Highest Quality & Reproducibility
- Global Partnerships
Specialties
- Target Discovery
- Generative Chemistry
- Multi-agent Generative Research Assistant
- Longevity AI
- Automated Lab Operating Environment
- Multiomics Age Prediction
- Biological Data Synthesis
Markets served
- Biotechnology
- Drug Discovery
- Generative AI
- Longevity
- Environmental Sustainability
Latest from Insilico Medicine
- Pharma.AI 2026: Q4 Year-End Update (Event · November 18, 2026)
Insilico Medicine scheduled a year-end update for its Pharma.AI platform to discuss advancements in generative AI software for scientific research and drug discovery. - The frontier AI benchmark for drug discovery. (Project update · November 16, 2026)
Insilico Medicine updated its unified research platform for evaluating AI capabilities across the drug discovery and development process, featuring curated datasets and specialized benchmarks.
Products by Insilico Medicine
- Insilico Medicine School (Course / digital content · From 0 USD)
Free educational courses in AI-driven drug discovery and healthcare innovation.
Services by Insilico Medicine
- Insilico Medicine Global Partnerships (Consulting & advisory)
Accelerating drug discovery through global strategic AI partnerships.
AI models by Insilico Medicine
- Precious1GPT (Science / biology model)
Transformer-based aging clock for biological age assessment and target identification.
AI agents by Insilico Medicine
- Life Star 2 (Workflow / back-office agent)
Automated lab operating environment for AI-driven autonomous research.
Clients and partners
3 clients and partners
Case studies
2 case studies
Upcoming events
- WHX 2026 (Conference · November 20, 2026)
- Pharma.AI 2026: Q4 Year-End Update (Webinar · December 1, 2026 · Online)
Documents
1 document
9 more products, services and AI on AntSpace. Sign up free to see the full catalog.
Leadership, clients, case studies, documents and every location on AntSpace. Sign up free to see them.